Adjuvant chemotherapy with temozolomide and liposomal doxorubicine in the first-line therapy of patients with glioblastoma – a phase-II trial
P Hau, T Jauch, B Hirschmann, E Drechsel, O Grauer, H Koch, C Wismeth, A Steinbrecher, U Bogdahn · Aktuelle Neurologie · 2004 · Heft 09
Bibliografische Angaben
Zusammenfassung
Background: Temozolomide (Temodar) recently showed promising results in the first-line therapy of glioblastoma(Stupp R, 2002). Pegylated liposomal doxorubicin (Caelyx) was successfully evaluated in patients with recurrent high-grade glioma (Fabel K, 2001; Hau P, 2002). Therefore, a combination of both agents seems promising. Here, we update data on a pilot phase II-trial using this regimen. Methods: We initiated a combination regimen consisting of temozolomide (TMZ) and liposomal doxorubicine (L-DOX) in the first-line therapy of patients with glioblastoma. TMZ is given during standard radiotherapy (initiation) a…
